AI · Decrypt
Moderna Stock Doubles on Cancer Breakthrough: Here’s What It Means
Compiled by KHAO Editorial — aggregated from 2 sources. See llms.txt for citation guidance.
✓ KHAO Verified
Moderna's personalized mRNA cancer shot cleared its first Phase 3 readout, and the market reacted like it had won more than a trial.
Key facts
- Shares of Moderna, which trades as MRNA, surged about 131% on Wednesday, more than doubling to near $148 after touching $163 intraday, a record one-day jump
- The companies said the Phase 3 INTerpath-001 trial of intismeran autogene plus Keytruda met its recurrence-free and distant-metastasis-free survival goals in patients whose stage IIB–IV melanoma
- With each shorted share now down almost $100, that is exactly the kind of pressure that can trigger a squeeze," ORTEX co-founder Peter Hillerberg said in a statement
- Keytruda, an anti-PD-1 drug, lifts the brakes on immune cells
Summary
Moderna (MRNA) jumped ~131% Wednesday after the Phase 3 INTerpath-001 trial of intismeran autogene plus Keytruda hit its RFS and DMFS endpoints in resected melanoma. Intismeran autogene is a personalized mRNA neoantigen therapy built from each patient's tumor mutations, paired with Merck's Keytruda immunotherapy. Traders shorting Moderna faced ~$4.8B in mark-to-market losses as the stock doubled; short interest sat at 13.5% of free float. Shares of Moderna, which trades as MRNA, surged about 131% on Wednesday, more than doubling to near $148 after touching $163 intraday, a record one-day jump.